Iovance Biotherapeutics
Iovance Biotherapeutics' revenue rose 60.6% to $264 million in fiscal 2025. Its operating margin was −153.1%, up from −240.9% a year earlier. Free cash flow was −$336 million. The diluted share count rose 23.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Iovance Biotherapeutics does
Iovance is a commercial-stage biopharmaceutical company, meaning it has approved products on sale. It makes cell therapies for solid-tumor cancers called tumor infiltrating lymphocyte (TIL) therapies. Each one is made from a patient's own immune cells, which are grown into very large numbers in a centralized manufacturing process and given back to the patient.
It has two commercial products. Amtagvi (lifileucel) is a one-time, individualized T cell therapy for adults with advanced melanoma, a skin cancer, who have already been treated. It is given with a short course of chemotherapy-type conditioning and Proleukin (aldesleukin), an interleukin-2 drug that Iovance also sells and that is used in other applications as well.
Amtagvi is approved in the United States and Canada. Approvals are pending in the United Kingdom, Australia and Switzerland. In the European Union, Iovance withdrew its first marketing application in July 2025. The company has restructured, including cutting its workforce.
Its biggest risks, as it describes them
- It has a history of operating losses and may never be profitable, even with Amtagvi approved.
- Its therapies are novel approaches, so the path to approval and acceptance is uncertain.
- Its newer manufacturing process may not meet FDA rules or lower the cost of making the therapy.
- It may not gain the expected benefits from its restructuring and workforce reductions.
- It faces competition from other drug companies and from non-profit institutions.
Income statement
Iovance Biotherapeutics lost money in fiscal 2025: a net loss of $391 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 504 | 472 | 280 | 324 | 297 |
| Debt incl. finance leases | 1 | 1 | 1 | 1 | — |
| Net debt (negative means net cash) | −503 | −471 | −279 | −323 | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 5.7x | 5.2x | 2.8x | 3.7x | 3.2x |
| Quick ratio | 5.7x | 5.2x | 2.7x | 3.3x | 2.8x |
Cash flow
Projections
Project Iovance Biotherapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Iovance Biotherapeutics says to expect
- Full year 2026: total product revenue
Iovance remains on track towards achieving its guidance range of $410 to $420 million in total product revenue in 2026.
Insider trades
No officer, director or 10% owner of Iovance Biotherapeutics reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 6 of 9 | — |
| Rule of 40 | — | 13,477.1% | −67.0% |
| Altman Z'' | −7.58 | −5.32 | −7.27 |
| Accruals ratio | −11.4% | −2.3% | −9.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | Pass | Fail |
| Revenue rose relative to assets | — | Pass | Pass |
| F-score | — | 6 of 9 | — |
Compare
Put Iovance Biotherapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics | FY25 | 60.6% | −153.1% | −127.6% | — | — | — | |
| Arvinas | FY25 | −0.3% | −45.1% | −105.0% | — | — | 5 | Compare |
| Ligand Pharmaceuticals | FY25 | 60.4% | 15.3% | 18.2% | 4.9% | −3.8x | 5 | Compare |
| Vericel | FY25 | 16.4% | 4.0% | 9.0% | — | — | — | Compare |
| Adaptive Biotechnologies | FY25 | 54.8% | −20.6% | −17.7% | −37.2% | — | 5 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | — | — | — | — | 1 | 164 | 264 |
| Revenue growth | — | — | — | — | — | — | — | — | 13,699.0% | 60.6% |
| Gross profit | — | — | — | — | — | — | — | 0 | 71 | 90 |
| Research and development | 27 | 72 | 100 | 166 | 202 | 259 | 295 | 333 | 276 | 300 |
| Operating income | −54 | −93 | −128 | −207 | −262 | −343 | −399 | −461 | −395 | −403 |
| Net income | −53 | −92 | −124 | −198 | −260 | −342 | −396 | −444 | −372 | −391 |
| Diluted EPS (US$) | −1.85 | −1.41 | −1.27 | −1.59 | −1.88 | −2.23 | −2.49 | −1.89 | −1.28 | −1.09 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow | ||||||||||
| Cash from operations | −33 | −79 | −101 | −159 | −205 | −228 | −293 | −362 | −353 | −302 |
| Capital expenditure | 2 | 1 | 1 | 7 | 47 | 38 | 20 | 22 | 11 | 34 |
| Free cash flow | −34 | −80 | −102 | −166 | −252 | −266 | −313 | −384 | −364 | −336 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 213 | 0 | 0 |
| Stock-based compensation | 19 | 12 | 20 | 24 | 41 | 70 | 84 | 63 | 110 | 62 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 166 | 145 | 386 | 307 | 635 | 504 | 472 | 280 | 324 | 297 |
| Debt incl. finance leases | — | — | — | — | — | 1 | 1 | 1 | 1 | — |
| Total assets | 172 | 155 | 481 | 345 | 768 | 777 | 664 | 780 | 910 | 913 |
| Total liabilities | 5 | 10 | 15 | 46 | 112 | 156 | 164 | 196 | 200 | 215 |
| Shareholders' equity | 167 | 146 | 466 | 299 | 656 | 622 | 500 | 585 | 710 | 699 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | 13.1% | 43.2% | 34.3% |
| Operating margin | — | — | — | — | — | — | — | −38,735.0% | −240.9% | −153.1% |
| Net margin | — | — | — | — | — | — | — | −37,345.4% | −226.8% | −148.4% |
| Free cash flow margin | — | — | — | — | — | — | — | −32,305.3% | −221.9% | −127.6% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | 13,477.1% | −67.0% |
| Return on capital | — | — | — | — | — | — | −428.6% | −217.5% | −90.1% | — |
| Return on equity | −39.0% | −58.9% | −40.4% | −51.6% | −54.3% | −53.5% | −70.6% | −81.9% | −57.5% | −55.5% |
| Return on assets | −38.1% | −56.3% | −38.9% | −47.9% | −46.6% | −44.3% | −54.9% | −61.5% | −44.0% | −42.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |